Asuragen to Present at 2019 Association for Molecular Pathology (AMP) Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Oct 30, 2019--
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host three corporate workshops and present multiple scientific posters highlighting their rapidly expanding product portfolio and industry collaborations at the upcoming 2019 Association for Molecular Pathology (AMP) Annual Meeting & Expo November 7-9 in Baltimore.
Asuragen’s sessions at the Corporate Workshop Day on November 6 will highlight user experiences with the new AmplideX® PCR/CE SMN1/2 Plus Kit ** and multiple assays within the company’s QuantideX® oncology product portfolio.
Asuragen will present four posters during the Scientific Poster Sessions, demonstrating its continuing innovation in translating molecular biology to impactful diagnostic products. Of note, a recent collaboration with ProteinSimple™, a Bio-Techne brand, combines the quantification of nucleic acid and protein markers relevant to targeted therapies and immune checkpoint inhibitors into a single, multiplexed workflow for Simple Western™ systems. “Diseases like non-small cell lung cancer require a multi-omics approach to better manage patients and this trend is likely to expand to other conditions as our knowledge of disease drivers grows,” said Robert Gavin, senior vice president, Analytical Systems Division at Bio-Techne. “Our collaboration with Asuragen represents a forward-looking approach for streamlining the analysis of clinically relevant targets across analyte types with a goal of transforming how these patients are diagnosed, treated, and managed.”
Asuragen’s Corporate Workshops will occur in Room 338 of the Baltimore Convention Center at 10am, 12pm, and 2pm, on Wednesday, respectively.
The following will be presented during Friday’s poster session from 2:30 – 3:30 p.m.
The following will be presented during Saturday’s poster session from 9:45-10:45 a.m.
“AMP affords us the unique opportunity to showcase our rapidly growing genetics and oncology product portfolios to a diverse audience spanning disease areas and practice types,” said Matthew McManus, MD, PhD, president and CEO of Asuragen. “As demonstrated through our numerous workshops, scientific posters, and collaborations, our best-in-class products for challenging genomic targets continue to provide simple, robust and reliable solutions for a highly dynamic customer base.”
The company will also have a presence at booth #2525 during the conference.
* For Research Use Only. Not for use in diagnostic procedures.
** Product in development. Specifications not finalized.
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191030005266/en/
CONTACT: Lynne Hohlfeld
SVP, Corporate Development and CFO
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH GENETICS ONCOLOGY
Copyright Business Wire 2019.
PUB: 10/30/2019 08:00 AM/DISC: 10/30/2019 08:01 AM